← brief for 2026-10-03 · Slowing decline

Group IVA Cytosolic Phospholipase A2 (cPLA2α): Pharmacological Inhibition Attenuates Kidney Inflammation and Fibrosis

Key takeaways

This study tested a drug on animals with kidney disease. It blocked an enzyme that causes inflammation and scarring. The drug slowed the damage in the animals. This was not tested in people yet.

Who did this work

Berit Johansen (Norwegian University of Science and Technology) · Said Movahedi Naini (Brigham and Women's Hospital) · Linn-Karina Selvik (Norwegian University of Science and Technology) · Astrid Jullumstrø Feuerherm (Norwegian University of Science and Technology) · Felicity J. Ashcroft (Norwegian University of Science and Technology) · Chang Wang (Brigham and Women's Hospital) · Samuel Mon-Wei Yu (Brigham and Women's Hospital) · Wenqing Yin (Brigham and Women's Hospital) · Konstantinos Alevizopoulos (Norwegian University of Science and Technology) · Oswald Quehenberger (University of California San Diego) · Edward A. Dennis (University of California San Diego) · Joseph Vincent Bonventre (Brigham and Women's Hospital)

Source

Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-10-02
https://doi.org/10.3390/biom16101430